New treatments for gonorrhoea to be developed

A £3.5 million investment has been made available to help develop new treatments for gonorrhoea and make them available to low and middle-income countries.

The investment is part of a continued partnership between the Department for Health and Social Care, the Global Antimicrobial Resistance Innovation Fund (GAMRIF), and the Global Antibiotic Research and Development Partnership (GARDP).

The investment will enable global access to treatment and will also fund GARDP’s development of oral antibiotic zoliflodacin, which is now in the last stage of clinical trials before reaching the market.

Zoliflodacin is one of the few antibiotics in development to specifically treat gonorrhoea and is significant as treatments for gonorrhoea are becoming less effective.

There have been cases of gonorrhoea developing resistance to recommended treatments, including in the UK.

Gonorrhoea is among the most common sexually-transmitted infections (STIs), with an estimated 87 million new cases globally every year.

Gonorrhoea has been identified as posing a significant threat to global health by the World Health Organization (WHO). There is now an urgent need for new treatment options, particularly for people in developing countries.

GARDP will now start pharmaceutical development activities for zoliflodacin, and will develop a new strategy for access and appropriate use in low- and middle-income countries that have a high number of cases of gonorrhoea.

GARDP plans to develop five new treatments for bacterial infections by 2025.

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho